Amylyx Pharmaceuticals, Inc. Common Stock
AMLX Real Time Price USDRecent trades of AMLX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Chris Jacobs House / R | Purchase $1,001 - $15,000 | Oct 12, 2022 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AMLX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Jul 16, 2025 Issue: Health Issues Medicare/Medicaid
-
$40,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid
-
$40,000 Jan 16, 2025 Issue: Health Issues Medicare/Medicaid
-
$40,000 Oct 18, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 16, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Feb 07, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 20, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 17, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 17, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 19, 2022 Issue: Medicare/Medicaid Health Issues
Estimated quarterly lobbying spending
AMLX Revenue by Segment or Geography
New patents grants
-
Patent Title: Compositions of bile acids and phenylbutyrate compounds Mar. 11, 2025
-
Patent Title: Compositions for improving cell viability and methods of use thereof Jan. 07, 2025
-
Patent Title: Methods and compositions for treating amyotrophic lateral sclerosis Nov. 12, 2024
-
Patent Title: Methods and compositions for treating amyotrophic lateral sclerosis Mar. 26, 2024
-
Patent Title: Compositions of bile acids and phenylbutyrate compounds Feb. 21, 2023
-
Patent Title: Compositions of bile acids and phenylbutyrate compounds Jan. 24, 2023
-
Patent Title: Compositions for improving cell viability and methods of use thereof Jul. 27, 2021
-
Patent Title: Compositions for improving cell viability and methods of use thereof Dec. 08, 2020
-
Patent Title: Compositions for improving cell viability and methods of use thereof Apr. 09, 2019
-
Patent Title: Compositions for improving cell viability and methods of use thereof Jan. 23, 2018
Federal grants, loans, and purchases
- $93,600 2024-03-20 00:00:00 Agency: Department of Veterans Affairs
- $204,837 2024-03-13 00:00:00 Agency: Department of Veterans Affairs
- $56,160 2024-02-27 00:00:00 Agency: Department of Veterans Affairs
- $46,800 2024-02-01 00:00:00 Agency: Department of Veterans Affairs
- $279,718 2023-12-20 00:00:00 Agency: Department of Veterans Affairs
- $93,600 2023-12-15 00:00:00 Agency: Department of Veterans Affairs
- $93,600 2023-11-08 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-10-06 00:00:00 Agency: Department of Veterans Affairs
- $748,940 2023-10-01 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-08-11 00:00:00 Agency: Department of Veterans Affairs
- $10,584 2023-07-28 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-07-20 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-07-06 00:00:00 Agency: Department of Veterans Affairs
- $1,478,874 2023-06-02 00:00:00 Agency: Department of Veterans Affairs
- $31,751 2023-06-02 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-06-01 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-05-18 00:00:00 Agency: Department of Veterans Affairs
- $355,679 2023-01-31 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $65,520 2023-01-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2023-01-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $10,530 2022-12-21 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2022-11-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded from public contracts
Recent insights relating to AMLX
Recent picks made for AMLX stock on CNBC
ETFs with the largest estimated holdings in AMLX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AMLX stock a Buy, Sell, or Hold?
- What is the price target for $AMLX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AMLX stock?
- Who owns the most shares of $AMLX stock?
- What funds own $AMLX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AMLX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.